- Home
- SMHI vs PLX Comparison
SMHI vs PLX Comparison
Compare SMHI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMHI
- PLX
- Stock Information
- Founded
- SMHI 1989
- PLX 1993
- Country
- SMHI United States
- PLX United States
- Employees
- SMHI N/A
- PLX N/A
- Industry
- SMHI Marine Transportation
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMHI Consumer Discretionary
- PLX Health Care
- Exchange
- SMHI Nasdaq
- PLX Nasdaq
- Market Cap
- SMHI 186.4M
- PLX 204.9M
- IPO Year
- SMHI N/A
- PLX 1998
- Fundamental
- Price
- SMHI $6.98
- PLX $1.86
- Analyst Decision
- SMHI
- PLX Strong Buy
- Analyst Count
- SMHI 0
- PLX 1
- Target Price
- SMHI N/A
- PLX $12.00
- AVG Volume (30 Days)
- SMHI 113.5K
- PLX 573.4K
- Earning Date
- SMHI 10-29-2025
- PLX 11-13-2025
- Dividend Yield
- SMHI N/A
- PLX N/A
- EPS Growth
- SMHI N/A
- PLX N/A
- EPS
- SMHI N/A
- PLX 0.07
- Revenue
- SMHI $245,311,000.00
- PLX $61,840,000.00
- Revenue This Year
- SMHI N/A
- PLX $14.53
- Revenue Next Year
- SMHI $8.81
- PLX $75.77
- P/E Ratio
- SMHI N/A
- PLX $26.49
- Revenue Growth
- SMHI N/A
- PLX 35.41
- 52 Week Low
- SMHI $3.63
- PLX $1.32
- 52 Week High
- SMHI $7.88
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- SMHI 51.51
- PLX 37.55
- Support Level
- SMHI $6.70
- PLX $1.71
- Resistance Level
- SMHI $7.27
- PLX $1.83
- Average True Range (ATR)
- SMHI 0.47
- PLX 0.13
- MACD
- SMHI -0.06
- PLX -0.03
- Stochastic Oscillator
- SMHI 37.84
- PLX 23.08
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.